Join Quince Therapeutics for a virtual key opinion leader (KOL) event featuring PH-ILD experts Aaron B. Waxman, MD, PhD (Brigham and Women’s Hospital) and Paul Yu, MD, PhD (Massachusetts General Hospital), as well as BOS expert Steven Hays, MD (UCSF Health), who will join company management to discuss the unmet need and current treatment landscape for PH-ILD and BOS.

The event will provide an overview of LAM-001, the Company’s proprietary once-daily inhaled DPI formulation of rapamycin (mTOR inhibitor), currently in Phase 2 clinical trials for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome post lung transplant (BOS). The KOLs will discuss mTOR inhibition as a potentially disease-modifying mechanism of action across these conditions, focusing on its role in suppressing pulmonary smooth-muscle hyperproliferation, limiting fibroblast-driven vascular and interstitial remodeling, and modulating inflammatory signaling, along with the unique potential advantages of delivering therapy through an inhaled route. Data from the recently presented Phase 2a trial of LAM-001 in pulmonary hypertension will be reviewed as well as the design and objectives of the ongoing Phase 2 BOS and Phase 2b PH-ILD studies.

A live question and answer session will follow the formal presentations.